DEUTETRABENAZINE

Deutetrabenazine inhibits VMAT2, reducing dopamine storage to treat tardive dyskinesia and chorea. Side effects include somnolence, depression risk, QT prolongation, and parkinsonism. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

DEUTETRABENAZINE demonstrates a highgranularity biochemical interaction profile spanning catalyticdomain modulation, multilayer signalling interference, mitochondrialnetwork recalibration, redoxstate restructuring, ionflux redistribution, membraneelectrochemical modulation, cytoskeletalarchitecture remodelling and transcriptionfactor axis reprogramming. Its molecular topology supports interactions with catalytic residues, allosteric regulatory surfaces, transmembrane helices, hydrophobic receptor pockets, nucleotidebinding cavities, redox-buffer modules and polymeric scaffolding proteinsenabling broad influence across metabolic, genomic, electrophysiological and structural regulatory networks.

Mechanistically, DEUTETRABENAZINE may reshape phosphorylationflow geometry across ERK/MAPK/JNK/p38 cascades, modulate PI3KAKT survivalpathway architecture, alter Gprotein coupling logic, redistribute Ca²⁺ microdomains, shift IP/DAG signal amplitude, and recalibrate cAMPPKA oscillatory behaviour. Mitochondrial effects include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, mitochondrialmembrane potential polarity shifts and ERmitochondria bidirectional stresssignal integration.

Advanced

  • Kinomescale catalyticcascade interference and pathway reconstruction
  • Ultraresolution receptor/ligand docking and conformationaltransition modelling
  • UPR/ERstress, mitophagy, autophagy and oxidativestress crosstalk research
  • Deep multiomics network reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tensionmapping, polymer turnover and mechanosignalling analytics
  • Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling
  • Machinelearning SAR/QSAR pipelines for predictive molecular optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation and antioxidantbuffer system collapse
  • Mitochondrial fragmentation, membranepotential failure or ETC inhibition
  • Severe Na⁺/K⁺/Ca²⁺ ionhomeostasis disruption
  • Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics
  • membrane-integrity failure and lipidbilayer thinning
  • NF-κB, STAT and IRF inflammatoryaxis hyperactivation
  • Engagement of multiaxis programmed-cell-death pathways
  • Epigenetic drift across methylation/acetylation domains

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C19H27NO3

Molecular Weight

323.5 g/mol

CAS Number

1392826-25-3

Storage Condition

Store at 25 °C (77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F).

Solubility

Sparingly soluble

Purity

Purity information is available upon request (COA).

Synonym

Deutetrabenazine; Austedo; Tetrabenazine-d6; SD-809; P341G6W9NB

IUPAC/Chemical Name

(3S,11bS)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one

InChl Key

MKJIEFSOBYUXJB-WEZHFFAMSA-N

InChl Code

InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m0/s1/i3D3,4D3

References

https://pubchem.ncbi.nlm.nih.gov/compound/73442840;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download